Metronidazole - Appili Therapeutics

Drug Profile

Metronidazole - Appili Therapeutics

Alternative Names: ATI 1501

Latest Information Update: 05 Dec 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Appili Therapeutics
  • Class Antibacterials; Antiprotozoals; Nitroimidazoles; Radiosensitisers; Small molecules
  • Mechanism of Action DNA synthesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Clostridium infections
  • New Molecular Entity No

Highest Development Phases

  • Phase I Anaerobic infections

Most Recent Events

  • 05 Dec 2017 Chemical structure information added
  • 08 Nov 2017 Phase-I clinical trials in Anaerobic infections (In volunteers) in Canada (PO) (NCT03337126)
  • 30 Oct 2017 The US FDA and Health Canada approves IND and CTA applications for metronidazole in Anaerobic infections
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top